Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged \>17 years (male and female)~* HCV infection PCR positive~* ALT \> 40 iu/ml~* Ishak fibrosis score (within last 5 years) \> 2, \< 5~* Informed consent~* Failed antiviral therapy for HCV in last 5 years~Exclusion Criteria:~* Patients requiring anticoagulation for existing clinical indications~* Active peptic ulcer disease~* Past history of haemorrhagic stroke~* Thrombocytopaenia (platelets count \< 100 x 109 /L)~* Clinical evidence of portal hypertension~* Known cerebrovascular abnormalities;~* HIV antibody positive;~* Alcohol abuse (\>40 unites/week)~* Menhorragia~* Pregnancy

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Warfarin anticoagulation (Type: EXPERIMENTAL): Anticoagulated with warfarin to maintain an INR of 2-3 between 8 and 16 weeks (treatment period).

Based on this trial design, predict the completion outcome and termination type (if applicable).